11 Paul Tudor Jones II AlloVir Trades
The first AlloVir trade was made in Q2 2021. Since then Paul Tudor Jones II bought shares four more times and sold shares on six occasions. The investor completely sold their stake between Q3 2023 and Q4 2024.
Avg closing price
Price range
Sold -2.16k shares
Q4 2024
Avg closing price
$2.20
Price range
$0.45
-
$10.91
Sold 32.6% shares (-1.04k shares)
Q3 2023
Avg closing price
$2.96
Price range
$2.15
-
$3.64
Increased shares by 175.2% (+2.04k shares)
Q2 2023
Avg closing price
$4.13
Price range
$3.17
-
$5.82
New holding (+1.16k shares)
Q1 2023
Avg closing price
$5.54
Price range
$3.94
-
$7.05
Sold -1.12k shares
Q4 2022
Avg closing price
$7.37
Price range
$4.70
-
$9.98
Sold 31.0% shares (-501 shares)
Q3 2022
Avg closing price
$6.78
Price range
$4.13
-
$8.79
Increased shares by 54.4% (+570 shares)
Q2 2022
Avg closing price
$4.56
Price range
$3.26
-
$7.06
Sold 2.3% shares (-25 shares)
Q1 2022
Avg closing price
$8.67
Price range
$6.75
-
$13.52
New holding (+1.07k shares)
Q4 2021
Avg closing price
$20.17
Price range
$12.94
-
$25.99
Sold -1.54k shares
Q3 2021
Avg closing price
$20.14
Price range
$16.97
-
$25.06
New holding (+1.54k shares)
Q2 2021
Avg closing price
$22.45
Price range
$19.44
-
$25.06
News about AlloVir Inc and Paul Tudor Jones II
AlloVir: ''Takes One To Know One''
Allovir''s lead product, posoleucel, is in Phase III clinical trials and targets six viral pathogens in immunocompromised individuals. Find out why ALVR stoc...